Recent news items are general market and sector news unrelated to NIMS's business operations.

• Mastercard CEO highlighted cybersecurity as their fastest-growing business segment, reflecting broader technology sector trends [N1].
• Home Depot reported a decline in customer transactions over five consecutive quarters, indicating retail sector challenges [N2].
• Taiwan stock market faced potential further declines, reflecting regional market volatility [N3].
• NuScale's potential deal for a large nuclear build-out was noted as significant in the energy sector [N4].
• Retirement spending trends may lead to higher taxes, impacting consumer financial planning [N5].
• Singapore stock market showed signs of potential downturn, indicating regional economic concerns [N6].
• Concerns were raised about Costco's stock trading at high forward earnings multiples [N7].
• The Trade Desk experienced challenges amid new AI developments, highlighting technology sector dynamics [N8].

The company has engaged in financing activities including convertible promissory notes and merger agreements, which may provide a structural basis for future corporate actions. Its historical technology in non-invasive therapeutic devices could potentially be leveraged if operations were to resume or pivot. The presence of experienced insiders and related-party financing arrangements indicates some level of ongoing management involvement.

NIMS has discontinued operations since 2019 and currently operates as a shell company with no products or inventory. It has a history of operating losses, negative working capital, and liquidity challenges, with a current ratio of 0.1 and net losses continuing into 2026. Governance weaknesses include lack of independent audit and compensation committees. The common stock is a penny stock with limited liquidity and trading risks. The company requires additional financing to continue as a going concern, with no assurance of obtaining such funding on acceptable terms.

NIMS currently does not operate an active business and has no products or inventory, thus it lacks a competitive moat. Historically, its non-invasive therapeutic acceleration platforms may have had niche applications, but with discontinued operations since 2019, the company does not maintain competitive advantages or barriers to entry in its prior market segment.

• Going Concern and Liquidity Risk: The company has recurring losses, an accumulated deficit of $29 million, and liquidity ratios indicating significant short-term financial constraints. Without additional financing, it may be unable to continue operations.
• Lack of Active Business Operations: Operations were discontinued in 2019, and the company currently has no products or inventory, limiting business activity and revenue generation.
• Governance and Control Risks: The company lacks independent audit and compensation committees, which may impair oversight and increase risk of management conflicts.
• Penny Stock and Market Risks: The common stock trades as a penny stock on OTC Pink, which may limit liquidity, increase volatility, and restrict investor ability to sell shares.
• Regulatory and Reporting Risks: The company has experienced delays in SEC filings, which could negatively impact investor confidence and market perception.

• Non-Invasive Monitoring Systems, Inc. (NIMS) was incorporated in Florida in 1980 and is headquartered in Miami, Florida [S1].
• The company's primary business previously involved research, development, manufacturing, marketing, and sales of non-invasive, motorized, whole body periodic acceleration (WBPA) platforms intended to aid temporary relief of minor aches and pains, muscle relaxation, and reduce morning stiffness [S1].
• Operations were effectively discontinued in May 2019, and the company is currently a shell company as defined by SEC rules [S1].
• NIMS currently has no inventory and no products available for sale [S1].
• The company has a history of operating losses and substantial accumulated deficit ($29.0 million as of July 31, 2025) [S1].
• Net losses for fiscal years ended July 31, 2025 and 2024 were $222,000 and $113,000 respectively [S1].
• As of June 30, 2026, the company reported cash and equivalents of $64,000 and current assets of $164,000, with current liabilities of $1,607,000, resulting in a current ratio of 0.1 and a cash ratio of 0.04, indicating liquidity challenges [S2].
• Net income for the quarter ended June 30, 2026 was a loss of $284,000, with basic and diluted EPS of -$0.28 [S2].
• The company has experienced delays in SEC filings but has taken measures to improve timeliness [S1, S2].
• NIMS does not have an independent audit or compensation committee; governance is conducted by directors, with potential conflicts noted [S1].
• The company does not anticipate paying dividends and its common stock trades as a penny stock on OTC Pink, with associated liquidity and trading risks [S1].
• The company has issued convertible promissory notes and amended agreements related to financing and merger transactions in 2026 [S2].